Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

被引：250

作者：

Hanna, Nasser H. ^{[1
]}

Schneider, Bryan J. ^{[2
]}

Temin, Sarah ^{[3
]}

Baker, Sherman, Jr. ^{[4
]}

Brahmer, Julie ^{[5
]}

Ellis, Peter M. ^{[6
]}

Gaspar, Laurie E. ^{[7
,8
]}

Haddad, Rami Y. ^{[9
]}

Hesketh, Paul J. ^{[10
]}

Jain, Dharamvir ^{[11
]}

Jaiyesimi, Ishmael ^{[12
]}

Johnson, David H. ^{[13
]}

Leighl, Natasha B. ^{[14
]}

Phillips, Tanyanika ^{[15
]}

Riely, Gregory J. ^{[16
]}

Robinson, Andrew G. ^{[17
]}

Rosell, Rafael ^{[18
]}

Schiller, Joan H. ^{[19
]}

Singh, Navneet ^{[20
]}

Spigel, David R. ^{[21
]}

Stabler, Janis O. ^{[22
]}

Tashbar, Joan ^{[22
]}

Masters, Gregory ^{[23
]}

机构：

[1] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA

[2] Univ Michigan Hlth Syst, Ann Arbor, MI USA

[3] Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA

[4] Virginia Commonwealth Univ, Richmond, VA USA

[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[6] Juravinski Canc Ctr, Hamilton, ON, Canada

[7] Univ Colorado, Sch Med, Denver, CO USA

[8] Banner MD Anderson Canc Ctr, Greeley, CO USA

[9] Affiliated Oncologists, Chicago Ridge, IL USA

[10] Lahey Hosp & Med Ctr, Burlington, MA USA

[11] Norton Canc Inst, Louisville, KY USA

[12] William Beaumont Hosp, Royal Oak, MI 48072 USA

[13] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[14] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[15] City Hope Natl Med Ctr, City Of Duarte, CA USA

[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[17] Queens Univ, Kingston Gen Hosp, Sch Med, Kingston, ON, Canada

[18] Catalan Inst Oncol, Barcelona, Spain

[19] Inova Schar Canc Inst, Falls Church, VA USA

[20] Postgrad Inst Med Educ & Res, Chandigarh, India

[21] Sarah Cannon Res Inst, Nashville, TN USA

[22] Circle Hope Canc Res, St Cloud, FL USA

[23] Helen F Graham Canc Ctr & Res Inst, Newark, DE USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 14期

关键词：

TYROSINE KINASE INHIBITORS; AMERICAN SOCIETY; OPEN-LABEL; PEMBROLIZUMAB; CHEMOTHERAPY; NIVOLUMAB; STATEMENT; FRAMEWORK; PATIENT; COST;

D O I：

10.1200/JCO.19.03022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSE The aim of this work is to provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) without driver alterations. A guideline update for patients with stage IV NSCLC with driver alterations will be published separately. METHODS The American Society of Clinical Oncology and Ontario Health (Cancer Care Ontario) NSCLC Expert Panel made updated recommendations based on a systematic review of randomized controlled trials from December 2015 to 2019. RESULTS This guideline update reflects changes in evidence since the previous guideline update. Five randomized controlled trials provide the evidence base. Additional literature suggested by the Expert Panel is discussed. RECOMMENDATIONS Recommendations apply to patients without driver alterations in epidermal growth factor receptor or ALK. For patients with high programmed death ligand 1 (PD-L1) expression (tumor proportion score [TPS] >= 50%) and non-squamous cell carcinoma (non-SCC), the Expert Panel recommends single-agent pembrolizumab. Additional treatment options include pembrolizumab/carboplatin/pemetrexed, atezolizumab/carboplatin/paclitaxel/bevacizumab, or atezolizumab/carboplatin/nab-paclitaxel. For most patients with non-SCC and either negative (0%) or low positive (1% to 49%) PD-L1, the Expert Panel recommends pembrolizumab/carboplatin/pemetrexed. Additional options are atezolizumab/carboplatin/nab-paclitaxel, atezolizumab/carboplatin/paclitaxel/bevacizumab, platinum-based two-drug combination chemotherapy, or non-platinum-based two-drug therapy. Single-agent pembrolizumab is an option for low positive PD-L1. For patients with high PD-L1 expression (TPS >= 50%) and SCC, the Expert Panel recommends single-agent pembrolizumab. An additional treatment option is pembrolizumab/carboplatin/(paclitaxel or nab-paclitaxel). For most patients with SCC and either negative (0%) or low positive PD-L1 (TPS 1% to 49%), the Expert Panel recommends pembrolizumab/carboplatin/(paclitaxel or nab-paclitaxel) or chemotherapy. Single-agent pembrolizumab is an option in select cases of low positive PD-L1. Recommendations are conditional on the basis of histology, PD-L1 status, and/or the presence or absence of contraindications. Additional information is available at www.asco.org/lung-cancer-guidelines.

引用

页码：1608 / +

页数：28

共 31 条

[1]

American Cancer Society, Cancer facts & figures for African Americans 2019-2021

[2]

[Anonymous], United States cancer statistics: 1999-2010 cancer incidence and mortality data

[3]

[Anonymous], 2024, Declining populations, rising disparities: Exploring racial and ethnic disparities in Safety and Justice Challenge Communities

[4] American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer [J].

Azzoli, Christopher G. ;

Baker, Sherman, Jr. ;

Temin, Sarah ;

Pao, William ;

Aliff, Timothy ;

Brahmer, Julie ;

Johnson, David H. ;

Laskin, Janessa L. ;

Masters, Gregory ;

Milton, Daniel ;

Nordquist, Luke ;

Pfister, David G. ;

Piantadosi, Steven ;

Schiller, Joan H. ;

Smith, Reily ;

Smith, Thomas J. ;

Strawn, John R. ;

Trent, David ;

Giaccone, Giuseppe .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6251-6266

[5] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[6] Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial [J].

Brahmer, Julie R. ;

Rodriguez-Abreu, Delvys ;

Robinson, Andrew G. ;

Hui, Rina ;

Csoszi, Tibor ;

Fulop, Andrea ;

Gottfried, Maya ;

Peled, Nir ;

Tafreshi, Ali ;

Cuffe, Sinead ;

O'Brien, Mary ;

Rao, Suman ;

Hotta, Katsuyuki ;

Zhang, Jin ;

Lubiniecki, Gregory M. ;

Deitz, Anne C. ;

Rangwala, Reshma ;

Reck, Martin .

LANCET ONCOLOGY, 2017, 18 (12) :1600-1609

[7] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

[8] Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia [J].

Dusetzina, Stacie B. ;

Winn, Aaron N. ;

Abel, Gregory A. ;

Huskamp, Haiden A. ;

Keating, Nancy L. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04) :306-311

[9] Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update [J].

Ferrell, Betty R. ;

Temel, Jennifer S. ;

Temin, Sarah ;

Alesi, Erin R. ;

Balboni, Tracy A. ;

Basch, Ethan M. ;

Firn, Janice I. ;

Paice, Judith A. ;

Peppercorn, Jeffrey M. ;

Phillips, Tanyanika ;

Stovall, Ellen L. ;

Zimmermann, Camilla ;

Smith, Thomas J. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) :96-+

[10] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

← 1 2 3 4 →